Ind-Swift Laboratories Reports Nil Deviation in Convertible Warrants Fund Utilization
Ind-Swift Laboratories Ltd 路 Others (Uncategorized) 路 30 Oct 2026, 2:15 am
Ind-Swift Laboratories Reports Nil Deviation in Convertible Warrants Fund Utilization Ind-Swift Laboratories confirmed zero deviation in proceeds utilization for the quarter ended 30th Sep'26 regarding its preferential issue of 70 lakh fully convertible warrants allotted on 17th Sep'26. Out of the total issue size of Rs. 137.20 crore, the company raised Rs. 34.30 crore and deployed Rs. 15.60 crore. Key capital outlays include Rs. 6.31 crore for manufacturing expansion and warehousing, Rs. 4.85 crore for subsidiary investments, Rs. 3.99 crore toward working capital, Rs. 0.33 crore for R&D, and Rs. 0.11 crore for general corporate purposes.
Original exchange filing (PDF)
More announcements from Ind-Swift Laboratories Ltd
- Please find enclosed transcript for earnings call held on November 04, 2026. 路 10 Nov 2026
- Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026. 路 05 Nov 2026
- Please find enclosed investor presentation on un-audited financial results for the quarter ended September 30, 2026 路 04 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of receipt of funds raised through preferential issue of 70,00,000 Fully Convertible Warrants 路 03 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of funds raised through Preferential Issue 2.6 Cr Fully Convertible Warrants 路 03 Nov 2026
- Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter .... 路 04 Nov 2026
- Press Release in respect of Unaudited Financial Results (Standalone & Consolidated) for the second quarter and half year ended September 30, 2026 路 30 Oct 2026
- Please refer attached pdf 路 30 Oct 2026
